The global respiratory inhaler devices market is on the cusp of significant transformation over the next decade, driven by a rising incidence of respiratory diseases, technological advancements, and ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...